Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payments ...

Genzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit, but diabetes drugs are still struggling. Net sales were €8,391 million ...

National Comprehensive Cancer Network (NCCN) presents preliminary data from a study demonstrating the usability of the Health ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

During the COVID pandemic, many of us have received multiple mRNA vaccines. New work by researchers at the VIB-UGent Center for Inflammation Research, Ghent University, and University Hospital Ghent, ...

The 43 patients treated with ravulizumab had a 33.2% greater reduction in average urine protein to creatinine ratio (UPCR) ...

The Massachusetts Life Sciences Center, the state’s quasi-governmental organization focused on economic development in the biotechnology sector, got a new leader this month as neurologist and ...

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent.

In the wake of the elimination diets, 38% of the parents reported no improvement in their child’s AD, 35% reported a 25% ...

The present findings reflect similar reports seen in other inflammatory skin disease, commented Afsaneh Alavi, MD, a ...

A total of 27 analyst ratings have been received for Biomarin Pharmaceutical, with the consensus rating being Outperform. The average one-year price target stands at $100.85, suggesting a potential 44 ...

Sanofi has been planning to spin off or sell its consumer unit to shore up new drug development spending at its core business ...